Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke

Archives of Neurology

Volumn 65, Issue 5, 2008, Pages 575-576

  Hallevi, Hen ^b   Grotta, James C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ARTERY OCCLUSION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG MECHANISM; EDITORIAL; HUMAN; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

BRAIN ISCHEMIA; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK ASSESSMENT; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 43549109482     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.5.575     Document Type: Editorial

References (9)

1. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.
2. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679-1685.
3. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282.
4. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke: The NINDS t-PA Stroke Study Group. Stroke. 1997;28(11):2109-2118.
5. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PCAJ, De Keyser J, Luijckx G-J. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65(5):607-611.
6. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59(6):862-867.
7. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38(3):967-973.
8. Sugg RM, Pary JK, Uchino K, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006;63(8):1057-1062.
9. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60(5):508-517.